Major Histocompatibility Class II Pathway Is Not Required for the Development of Nonalcoholic Fatty Liver Disease in Mice

Figure 5

Effect of 4-week CCl₄ treatment on liver and blood glucose in wild-type and MHCII^Δ/Δ mice. Open bars represent oil-treated wild-type (WT-oil), closed bars CCl₄-treated wild-type (WT-CCl₄), gray bars oil-treated MHCII^Δ/Δ mice, and semiclosed bars CCl₄-treated MHCII^Δ/Δ mice (wild-type oil: 𝑛=7, MHCII^Δ/Δ oil: 𝑛=5, wild-type CCl₄: 𝑛=11, MHCII^Δ/Δ CCl₄: 𝑛=9). Data are presented as mean ± SEM. (a) Liver weight. (b) Fasting blood glucose decreased after the CCl₄ treatment in both groups. (c), (d) Strong increase in fasting plasma ALT and AST was observed after the CCl₄ treatment. ^a,b,c𝑃<0.05, ANOVA and Tukey Kramer HSD test. Different letters indicate the significant difference between groups.

(a)

(b)

(c)

(d)